Drug treatment of Alzheimer's disease: Effects on caregiver burden and patient quality of life

Drugs and Aging

Volumn 8, Issue 1, 1996, Pages 47-55

  Hollister, Leo ^a   Gruber, Nelson ^a  

^a University of Texas Harris County Psychiatric Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCARNITINE; AMANTADINE DERIVATIVE; CALCIUM ANTAGONIST; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DIHYDROERGOTOXINE MESILATE; MEMANTINE; NIMODIPINE; NOOTROPIC AGENT; PHOSPHATIDYLCHOLINE; PIRACETAM; SELEGILINE; TACRINE; VELNACRINE;

ALZHEIMER DISEASE; CAREGIVER; CLINICAL TRIAL; COST; DISEASE SEVERITY; DRUG RESPONSE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER DYSFUNCTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; REVIEW;

EID: 0030049889     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199608010-00008     Document Type: Review

References (58)

1. Anonymous. Dementia - the quiet epidemic (editorial). BMJ 1978; 1: 1-2
2. Clarfield AM. The reversible dementias: do they reverse? Ann Intern Med 1988; 109: 476-86
3. Perry RH, Irving D, Blessed G, et al. Dementia in old age: identification of a clinically and pathologically distinct disease category. Adv Neurol 1990; 51: 41-6
4. Moseley I. Imaging the adult brain. J Neurol Neurosurg Psychiatry 1995; 58: 7-21
5. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44
6. Leonard B, Morris JC. Diagnosis. In: Terry RD, Katzman R, Blick KL, editors. Alzheimer's disease. New York: Raven Press, 1994: 1-26
7. American Psychiatric Association, Committee on Nomenclature and Statistics. Diagnostic and statistical manual of mental disorders, 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987
8. World Health Organization. The ICD-10 classification of mental and behavioral disorders; clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992: 45-9
9. Tinter RJ, Weiner MF, Bonte FJ. The dementia workup. In: Weiner MF, editor. The dementias, diagnosis and management. Washington, DC: American Psychiatric Press, Inc., 1991:47-75
10. Cummings JL, Benson DF, editors. Dementia: a clinical approach. 2nd ed. Boston: Butterworth-Heinemann, 1992
11. Emery VOB, Oxman TE, editors. Dementia: presentation, differential diagnosis, and nosology. Baltimore: Johns Hopkins University Press, 1994
12. Holstein MF, Folstein SE, McHugh PR. Mini-mental state, a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98
13. Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 1975; 23: 433-41
14. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114: 797-811
15. Storandt M, Botwinick J, Danziger WL, et al. Psychometric differentiation of mild senile dementia of the Alzheimer type. Arch Neurol 1984; 41: 497-9
16. Eslinger PJ, Damasio AR, Benton AL, et al. Neuropsychologic detection of abnormal mental decline in older persons. JAMA 1985; 253: 670-4
17. Venn RD. The Sandoz Clinical Assessment-Geriatric (SCAG) scale. A general purpose psychogeriatric rating scale. Gerontology 1983; 29: 185-8
18. Hollister LE, Yesavage J. Ergoloid mesylates for senile dementia: unanswered questions. Ann Intern Med 1984; 100: 894-8
19. Rose WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64
20. Reisberg B, Ferris SH, de Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-39
21. Hughes CP, Berg L, Danziger WL. A clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 556-72
22. Dejong R, Osterland OW, Roy GW. Measurement of quality-of-life changes in patients with Alzheimer's disease. Clin Ther 1989; 11: 545-54
23. Knopfman DS, Knapp MJ, Gracon SI, et al. The Clinician Interview Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994; 44: 2315-21
24. Clinical Global Assessment scale (CGI). In: Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville (MD): US Dept of Health Education and Welfare, National Institute of Mental Health, 1976: 218-22
25. Lawton MP, Brody EM. Assessment of older people: self maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 176-86
26. Spiegel R, Brunner C, Ermini-Funfschilling D, et al. A new behavioral assessment scale for geriatric out-and in-patients: the NOSGER (Nurses' Observation Scale for Geriatric Patients). J Am Geriatr Soc 1991 Apr; 39 (4): 339-47
27. Dippel RL. The caregivers. In: Dippel RL, Hutton JT, editors. Caring for the Alzheimer's patient: a practical guide. 2nd ed. Buffalo: Prometheus Books, 1991: 17
28. Zarit SH, Ory NK, Zarit JM. The hidden victims of Alzheimer's disease: families under stress. New York: York University Press, 1985
29. Elliot GR, Eisdorfer C, editors. Stress and human health. New York: Springer Verlag, 1982
30. Haley E, Levine EG, Brown SL, et al. Stress, appraisal, coping, and social support as predictors of adaptational outcome among dementia caregivers. Psychol Aging 1987; 2: 323-30
31. Hansen D, Hill R. Families under stress. In: Chistensen H, editor. Handbook of marriage and the family. Chicago: Rand-McNally, 1964: 782-819
32. Montgomery RJ, Stull DE, Borgalta EF. Measurement and the analysis of burden. Res Aging 1985; 7: 137-52
33. Biegal DE, Sales E, Schulz R. Theoretical perspectives on caregiving. In: Biegal DE, Sales E, Schulz R, editors. Family caregiving in chronic illness - Alzheimer's disease, cancer, heart disease, mental illness, and stroke. Newbury Park: Sage Publications, 1991: 38-49
34. Beck AT, Beck RT. Screening depressed patients in family practice: a rapid technique. Postgrad Med 1972; 81-5
35. Radloff LS. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Measure 1977; 1: 385-401
36. Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. Psychol Med 1979; 9: 139-45
37. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978; 35: 837-44
38. Schulz R, Williamson GM. Health effects of caregiving: prevalence of mental and physical illness in Alzheimer's caregivers. In: Light E, Niederehe G, Lebowita BD, editors. Stress effects on family caregivers of Alzheimer's patients. New York: Springer Publishing Company, 1994: 38-63
39. Cooper J. Drug treatment of Alzheimer's disease. Arch Intern Med 1991; 151: 245-9
40. Rossor MN. Management of neurological disorders: dementia. J Neurol Neurosurg Psychiatry 1994; 57: 1451-6
41. Pepeu G. Memory disorders: novel treatments, clinical perspective. Life Sci 1994; 55: 2189-94
42. Sarter M. Taking stock of cognition enhancers. Trends Pharmacol Sci 1991; 13: 456-61
43. Khatchaturian ZS, Phelps CH, Buckholz NS. The prospect of developing treatments for Alzheimer disease. In: Terry RD, Katzman R, Blick KL, editors. Alzheimer's disease. New York: Raven Press, 1994: 445-54
44. Pathy MSJ. The pharmacological management of cognitive impairment in the demented patient. Prog Neuropsych Biol Psychiatry 1993; 17: 515-24
45. Thal LJ. Clinical trials in Alzheimer disease. In: Terry RD, Katzman R, Blick KL, editors. Alzheimer's disease. New York: Raven Press 1994:431-44
46. Schneider LS, Olin JT. Overview of clinical trials of hydergine in dementia. Arch Neurol 194; 51: 787-98
47. Thompson II TL, Filley CM, Mitchell WD, et al. Lack of efficacy of hydergine in patients with Alzheimer's disease. N Engl J Med 1990; 323: 445-8
48. Whitehouse P. Treatment of Alzheimer disease. Alz Dis Assoc Disord 1991; 5 (1 Suppl.): 32S-36S
49. Farlow M, Gracon SI, Hershey LA, et al. for the Tacrine Study Group. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268: 2523-9
50. Davis KL, Thal LJ, Gamzu E, et al. for The Tacrine Collaborative Study Group. A double-blind placebo-controlled study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327: 1253-9
51. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985-91
52. Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer's disease. Lancet 1991; 337: 989-92
53. Gauthier S, Bouchard R, Lamontagne A, et al. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, cross-over, multicenter study. N Engl J Med 1990; 322: 1272-6
54. Siegfried K. The efficacy of cholinergic drugs in patients with Alzheimer's disease - focus on the aminacridines. Hum Psychopharm 1995; 10: 89-96
55. Spagnoli A, Lucca U, Mensco G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer disease. Neurology 1991; 41: 1726-32
56. Ditzler K. Efficacy and tolerability of memantine inpatients with dementia syndrome. A double-blind placebo controlled trial. Arzneimittel Forschung 1991; 41: 773-9
57. Tarlot PN, Sunderland T, Weingartner H, et al. Cognition effects of 1-deprenyl in Alzheimer's disease. Psychopharmacology 1987; 91: 489-95
58. Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry 1991; 27: 1133-42